Bajaj Healthcare Ltd (BAJAJHCARE) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management reaffirmed its long-term revenue target of 900-1,000 crores by FY29, supported by annual capex of 50-60 crores post-FY27.
- The formulations business is expected to become 45-50% of total revenue within four years, a significant shift from the current API-dominated mix.
- The new peptide API plant, focusing on pharma, cosmetic, and nutraceutical segments, is projected to generate 70-100 crores in its first full year (FY29).
Performance Overview
- The company reported strong business momentum and progress on strategic priorities, with revenue and profit growing significantly.
- Formulation business rebounded strongly, and API exports showed robust growth, together crossing 100 crores in quarterly revenue.
- The company received DCGI approval for Cenobamate, becoming the first in India to manufacture and market this anti-seizure medicine.
- Strategic investments in manufacturing capabilities are underway, including a new peptide plant and an oncology API facility.
- The leadership team was strengthened with several key appointments to drive future growth and professionalize the organization.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.